Insiders · CDT

CDT insider transactions

CDT Equity Inc. (CDT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

CDT insiders

Everyone who has filed a Form 3, 4, 5 or 144 at CDT Equity Inc., latest first. Follow anyone to get their next filing.

• Andrew ReganChief Executive Officer, Director, since September 2023
• Mark Andrew Taylor10% owner, since February 2026
• Ulrik K OlsenDirector, since April 2026
• Chele Chiavacci FarleyDirector
• James BlighCFO, Director, since September 2023
• Simon Jeremy FryDirector, since December 2024
• Freda C Lewis-HallDirector, since September 2023
• Sarborg Ltd10% owner, since March 2025
• Faith L. CharlesDirector, since September 2023
• David TapolczayChief Executive Officer, Director, since September 2023
• Nirland Ltd10% owner, since August 2024-$298K
• Adam SragoviczChief Financial Officer
• Jennifer Isacoff McNealeyDirector, since September 2023
• Jack Kendrick HeilbronInsider
• Shaolin Capital Management LLC10% owner, since February 2023

Recent Form 3, 4, and 5 filings for CDT

• 12d
  SEC Form 4 filed by CDT Equity Inc.

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 12d
  Amendment: SEC Form 4/A filed by CDT Equity Inc.

  4/A - CDT Equity Inc. (0001896212) (Issuer)
• 12d
  SEC Form 3 filed by CDT Equity Inc.

  3 - CDT Equity Inc. (0001896212) (Issuer)
• 67d
  Chief Executive Officer Regan Andrew acquired 5,436,830 shares and sold 290 shares (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 138d
  Large owner Taylor Mark Andrew sold $2,945,586 worth of shares (2,068,000 units at $1.42) (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 178d
  Chief Executive Officer Regan Andrew was granted 247,401 shares (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 192d
  New insider Olsen Ulrik K claimed ownership of 233,585 shares (SEC Form 3)

  3 - CDT Equity Inc. (0001896212) (Issuer)
• 223d
  SEC Form 4 filed by Taylor Mark Andrew

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 223d
  SEC Form 3 filed by new insider Taylor Mark Andrew

  3 - CDT Equity Inc. (0001896212) (Issuer)
• 258d
  Director Farley Chele Chiavacci was granted 10,553 shares, increasing direct ownership by 160% to 17,157 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 321d
  Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 412d
  Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 415d
  CFO Bligh James was granted 480,000 shares, increasing direct ownership by 2,000,000% to 480,024 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 439d
  Director Fry Simon Jeremy was granted 35,000 shares, increasing direct ownership by 1,789% to 36,956 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 439d
  Director Farley Chele Chiavacci was granted 35,000 shares, increasing direct ownership by 1,477% to 37,369 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 439d
  Director Lewis-Hall Freda C was granted 35,000 shares, increasing direct ownership by 1,010% to 38,466 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 513d
  Chief Executive Officer Regan Andrew was granted 154,799 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 550d
  New insider Sarborg Ltd claimed ownership of 1,853,933 shares (SEC Form 3)

  3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 570d
  Director Charles Faith L. was granted 115,194 shares, increasing direct ownership by 230% to 165,238 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 586d
  Director Lewis-Hall Freda C was granted 47,612 shares, increasing direct ownership by 1,087% to 51,991 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 586d
  Director Fry Simon Jeremy was granted 29,354 shares, increasing direct ownership by 1,468% to 31,354 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 586d
  Director Farley Chele Chiavacci was granted 32,022 shares, increasing direct ownership by 911% to 35,537 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 586d
  Director Charles Faith L. was granted 46,629 shares, increasing direct ownership by 1,365% to 50,044 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 688d
  SEC Form 4 filed by Director Lewis-Hall Freda C

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 688d
  SEC Form 4 filed by Director Farley Chele Chiavacci

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 688d
  SEC Form 4 filed by Director Charles Faith L.

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 688d
  SEC Form 4 filed by Director Fry Simon Jeremy

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 688d
  New insider Fry Simon Jeremy claimed ownership of 200,000 shares (SEC Form 3)

  3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 718d
  SEC Form 4 filed by Chief Executive Officer Tapolczay David

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 718d
  Director Lewis-Hall Freda C was granted 437,976 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 718d
  SEC Form 4 filed by Interim CFO Bligh James

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 718d
  Director Charles Faith L. was granted 341,594 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 718d
  Director Farley Chele Chiavacci was granted 299,238 shares, increasing direct ownership by 572% to 351,510 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 762d
  Large owner Nirland Ltd sold $393,439 worth of shares (3,808,000 units at $0.10) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 767d
  Large owner Nirland Ltd sold $297,644 worth of shares (2,600,000 units at $0.11) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 780d
  Director Regan Andrew disposed of 1,100,000 shares, acquired 1,100,000 shares and sold $4,592,487 worth of shares (15,301,068 units at $0.30) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 817d
  New insider Nirland Ltd claimed ownership of 12,500,000 shares (SEC Form 3)

  3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 880d
  Director Farley Chele Chiavacci was granted 37,272 shares, increasing direct ownership by 248% to 52,272 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 880d
  Interim CFO Bligh James was granted 37,272 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 907d
  Sragovicz Adam returned 74,545 units of Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 907d
  SEC Form 4 filed by Mcnealey Jennifer Isacoff

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 928d
  SEC Form 4 filed by Lewis-Hall Freda C

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 928d
  SEC Form 4 filed by Tapolczay David

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 928d
  SEC Form 4 filed by Farley Chele Chiavacci

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)